Goldman Sachs Group Inc. Reiterates Buy Rating for GlaxoSmithKline plc (GSK)
GlaxoSmithKline plc (LON:GSK)‘s stock had its “buy” rating reissued by equities research analysts at Goldman Sachs Group Inc. in a research note issued on Tuesday. They presently have a GBX 1,800 ($23.50) target price on the stock. Goldman Sachs Group Inc.’s price objective would indicate a potential upside of 10.46% from the company’s current price.
GSK has been the subject of several other reports. Credit Suisse Group AG reaffirmed a “neutral” rating and set a GBX 1,800 ($23.50) target price on shares of GlaxoSmithKline plc in a research report on Thursday, July 14th. S&P Global Inc. set a GBX 1,650 ($21.54) target price on GlaxoSmithKline plc and gave the stock a “neutral” rating in a research report on Wednesday, July 27th. Beaufort Securities reaffirmed a “buy” rating on shares of GlaxoSmithKline plc in a research report on Tuesday, June 21st. BNP Paribas reaffirmed a “neutral” rating on shares of GlaxoSmithKline plc in a research report on Friday, July 29th. Finally, Bryan, Garnier & Co reaffirmed a “buy” rating on shares of GlaxoSmithKline plc in a research report on Thursday, July 28th. Three research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and eight have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of GBX 1,676.44 ($21.88).
GlaxoSmithKline plc (LON:GSK) opened at 1632.00 on Tuesday. The stock’s 50 day moving average price is GBX 1,654.01 and its 200 day moving average price is GBX 1,531.21. The firm’s market capitalization is GBX 79.33 billion. GlaxoSmithKline plc has a 52-week low of GBX 1,227.50 and a 52-week high of GBX 1,716.50.
The firm also recently announced a dividend, which will be paid on Thursday, October 13th. Shareholders of record on Thursday, August 11th will be issued a dividend of GBX 19 ($0.25) per share. The ex-dividend date is Thursday, August 11th. This represents a yield of 1.12%.
In other GlaxoSmithKline plc news, insider Cartwright,Stacey bought 461 shares of the stock in a transaction on Friday, July 1st. The shares were acquired at an average price of GBX 1,559 ($20.35) per share, with a total value of £7,186.99 ($9,381.27). Also, insider Slaoui,Moncef bought 28 shares of the stock in a transaction on Friday, August 12th. The shares were acquired at an average cost of GBX 2,208 ($28.82) per share, for a total transaction of £618.24 ($807.00).
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.